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Abstract
Stroke continues to be the third-leading cause of death and disability worldwide. The limited availability of diagnostic tools 
approved therapeutics and biomarkers that help monitor disease progression or predict future events remain as the major chal-
lenges in the field of stroke medicine. Hence, attempts to discover safe and efficacious therapeutics and reliable biomarkers 
are of paramount importance. MicroRNAs (miRNAs) are a class of non-coding RNAs that play important roles in regulating 
gene expression. Since miRNAs also play important roles in key mechanisms associated with the pathogenesis of stroke, 
including energy failure, inflammation and cell death, it is possible that miRNAs may serve as reliable blood-based mark-
ers for risk prediction, diagnosis and prognosis of ischaemic stroke. Discovery of better neurological outcome and smaller 
cerebral infarcts in animal models of ischaemic stroke treated with miRNA agomirs or antagomirs indicate that miRNAs 
may also play a cerebrovascular protective role after an ischaemic stroke. Nonetheless, further evidences on the optimum 
time for treatment and route of administration are required before effective translation of these findings into clinical practice. 
Bearing these in mind, this paper reviews the current literature discussing the involvement of miRNAs in major pathologies 
associated with ischaemic stroke and evaluates their value as reliable biomarkers and therapeutics for ischaemic stroke.
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Introduction
Stroke is characterised by an acute neurological dysfunction 
lasting for more than 24 h or leading to death with no appar-
ent cause other than vascular origin. There are two major 
types of stroke depending on aetiology: ischaemic and haem-
orrhagic. Ischaemic strokes stem from the occlusion of the 
blood vessel leading to or within the brain due to formation 
of a thrombus (thrombotic strokes) or an embolus (embolic 
strokes). Haemorrhagic strokes, on the other hand, result 
from the rupture of an artery within (intracerebral haemor-
rhage) or on the surface (subarachnoid haemorrhage) of the 
brain. Ischaemic strokes account for approximately 85% of 
all strokes and therefore represent the main subtype of stroke 
(Benjamin Emelia et al. 2019; Johnson et al. 2019).
Due to high rate of mortality, morbidity and socio-eco-
nomic costs for patients, families and society in general, 
stroke constitutes one of the major healthcare issues in the 
world (Johnson et al. 2019; WHO 2019). Considering that 
the majority of strokes are preventable, an appropriate risk 
assessment and integrated strategy for stratification of the 
general population via predictive biomarkers may be the best 
option to reduce the number of future strokes in individuals 
who are classified at high risk (Powers 2020). The diagnos-
tic modality for stroke cannot merely rely on neuroimaging 
techniques such as computed tomography (CT) and magnetic 
resonance imaging (MRI) which are expensive, somewhat 
ineffective to recognise early signs of infarct and unavail-
able in most hospitals in low-income countries (Parody et al. 
2015; Wardlaw Joanna et al. 2007). Similarly, therapeutic 
strategy cannot solely rely on recombinant tissue plasmino-
gen activator (rtPA) and mechanical thrombectomy, as such 
strategies are expensive, fraught with high risk of haemor-
rhagic complications and require highly trained personnel 
(Kadir and Bayraktutan 2020). In addition, the unavailabil-
ity of prognostic biomarkers for stroke has to be addressed, 
so that unfavourable outcomes, notably haemorrhagic 
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transformation and stroke recurrence, can be anticipated at 
an early stage (Faraji et al. 2013; van Kranendonk Katinka 
et al. 2019). Taken together, point-of-care diagnostic tool, 
reliable prognostic marker as well as low-cost and widely 
accessible treatment strategy are urgently needed to prevent 
people from getting stroke and also to improve stroke care 
and interventions once they have had a stroke.
Accumulating evidence has shown the existence of an 
intricate relationship between microRNAs (miRNAs) and 
the major mechanisms, including energy failure, excito-
toxicity, oxidative stress, inflammation, cell death and 
blood–brain barrier (BBB) disruption, implicated in the 
pathogenesis of ischaemic stroke (Li et al. 2013). As a con-
sequence, miRNAs have attracted a great deal of attention 
as potential blood-based biomarkers to predict, diagnose and 
evaluate the prognosis of ischaemic stroke and also as thera-
peutics to treat ischaemic stroke (Vijayan and Reddy 2016a; 
Xu et al. 2018). Such comprehensive approach, ranging from 
an accurate prediction of healthy individuals who may suf-
fer an ischaemic stroke in the future to an efficacious treat-
ment of ischaemic stroke, is urgently required to effectively 
address the deteriorating impact of stroke.
Biogenesis of miRNA
miRNAs are small non-coding RNAs that consist of approxi-
mately 20–22 nucleotides and play a crucial role in the post-
transcriptional regulation of gene expression. The majority 
of miRNAs are initially transcribed from genomic DNA 
by RNA polymerase II to generate primary miRNA (pri-
miRNA). Pri-miRNA consists of long nucleotide chains, 
hundreds or thousands of base pairs in length and con-
taining at least one hairpin loop (Treiber et al. 2019). In 
general, biogenesis of miRNA includes a canonical and a 
non-canonical pathway. In canonical pathway, pri-miRNA 
is recognised by the nuclear enzyme DiGeorge Syndrome 
Critical Region 8 (DGCR8) and cleaved by RNAase III 
endonuclease Drosha, which in turn forms precursor 
miRNA (pre-miRNA). Subsequently, exportin-5 translo-
cates pre-miRNA from the nucleus into cytoplasm and forms 
22-nucleotide double-stranded RNA, containing the mature 
miRNA guide strand and the passenger (miRNA*) strand 
through a cleavage process by another RNAase III endonu-
clease enzyme, Dicer (Kumar and Reddy 2016). In contrast, 
in non-canonical pathway, miRNA biogenesis is performed 
through Drosha- or Dicer-independent pathways. The nota-
ble class of Drosha-independent pathways are the mirtrons 
which originate from introns that function as pre-miRNAs 
once spliced and hence do not require cleavage by Drosha 
and are directly exported to the cytoplasm for processing 
by Dicer (Ruby et al. 2007). Conversely, pre-miRNA in 
Dicer-independent pathway is produced by Drosha, without 
bypassing the cleavage process by Dicer and immediately 
exported to the cytoplasm (Yang et al. 2010). Ultimately, 
all these pathways lead to a process called RNA-induced 
silencing complex (RISC), in which the double-stranded 
miRNA is handed over to Argonaute, which in turn selects 
one strand (guide strand) to become the mature miRNA and 
discards the other strand (miRNA*). Finally, most mature 
miRNAs bind to the 3′untranslated region (3′UTR) of target 
messenger RNA (mRNA) to promote mRNA degradation 
and translational inhibition (O’Brien et al. 2018).
Although an overwhelming majority of miRNAs suppress 
the activity of their target mRNA, growing evidence reveals 
that some miRNAs upregulate gene expression by regulating 
miRNA-associated decay elements and blocking the func-
tion of repressive protein and thus activating other targets 
(Vasudevan 2012). Furthermore, several miRNAs appear to 
target the 5′UTR- rather than 3′UTR-binding site of mRNA 
(Ørom et al. 2008). To the best of our knowledge, the inter-
action between miRNA and 5′UTR-binding site has not been 




The obstruction of cerebral blood flow during an ischaemic 
stroke significantly reduces the supply of oxygen and glu-
cose to the brain tissue whereby hampers adequate genera-
tion of adenosine triphosphate (ATP). This in turn impairs 
the function of ion pumps, causes uncontrolled calcium 
Fig. 1  The involvement of key miRNAs and their targets in major 
mechanisms associated with ischaemic stroke. Abbreviations: AIF 
apoptosis-inducing factor; AMPAR α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptor; APAF-1 apoptotic protease-
activating factor-1; AQP-1 aquaporin-1; AQP4 aquaporin-4; Bcl-2 
B-cell lymphoma-2; Bcl-xL B-cell lymphoma-extra large; Ca2+ cal-
cium ions; CAD caspase-activated Dnase; DISC death-inducing sig-
nalling complex; FADD Fas-associated protein with death domain; 
FasL Fas ligand; FasR Fas receptor; Fe2+ ferrous ion; Glur-2 glu-
tamate receptor-2; GPx glutathione peroxidase; GSH glutathione; 
H2O2 hydrogen peroxide; ICAD inhibitor of caspase-activated Dnase; 
ICAM-1 intercellular adhesion molecule-1; IL-10 interleukin-10; IL-
6 interleukin-6; MCP-1 monocyte chemoattractant protein-1; miRNA 
microRNA; NMDAR N-methyl-d-aspartate receptor; NO nitric oxide; 
NOS nitric oxide synthase; Nox nicotinamide adenine dinucleotide 
phosphate oxidase; Nrf-2 nuclear factor erythroid-2; O2 oxygen; 
O2− superoxide anion; OH− hydroxyl radical; ONOO− peroxynitrite; 
PARP poly(ADP-Ribose) polymerase; PKC protein kinase C; SDF-
1 stromal cell-derived factor-1; SMAC second mitochondria-derived 
activator of caspase; SOD superoxide dismutase; TNF tumour necro-
sis factor; TRAIL TNF-related apoptosis-inducing ligand; TRAIL-R 
TNF-related apoptosis-inducing ligand receptor; VCAM-1 vascular 
cell adhesion molecule-1; XIAP X-linked inhibitor of apoptosis pro-
tein, ZO-1 zonula occludens-1
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depolarisation and triggers excessive production of exci-
totoxic neurotransmitters, notably glutamate and aspartate 
(Fig. 1). These then perturb the inner and outer mitochon-
drial membrane permeabilities and, as a result, lead to oxida-
tive stress and induce cell death by augmenting the release of 
superoxide anion and cytochrome-c, respectively (Lai et al. 
2014).
Increases in certain miRNAs, such as miR-107, closely 
followed by an increase in glutamate expression have been 
reported in both animal models and patients with ischaemic 
stroke (Yang et al. 2014). Decreased apoptosis and gluta-
mate accumulation in neuronal cells exposed to ischaemia/
reperfusion injury and in rats subjected to middle cerebral 
artery occlusion (MCAO) treated with miR-107 inhibitor 
corroborate the seminal role of miR-107 in the regulation 
of excitotoxicity during and after cerebral ischaemic injury. 
Luciferase assays aiming to identify the specific target 
genes for this particular miRNA have revealed that miR-107 
reduces glutamate accumulation by directly binding to GLT-
1, the most abundant glutamate transporter (Li et al. 2015; 
Yang et al. 2014). Similarly, overexpression of miR-223 has 
been shown to reduce neuronal excitability and neuronal 
cell death treated with a lethal dose of excitotoxic injury 
(500 μM of NMDA) as well as in mice subjected to a severe 
excitotoxicity (20 nmols of NMDA was directly injected into 
the striatum) or transient global ischemia. Suppression of 
glutamate receptor subunits Glur-2 and NR2B in the brain 
appears to account for the excitotoxicity regulatory effect of 
miR-223 (Harraz et al. 2012).
Inflammation
Inflammation represents one of the major pathologies lead-
ing to neurovascular injury and hyperpermeability follow-
ing an acute cerebral ischaemic injury and is mostly initi-
ated by activation of various pro-inflammatory cytokines, 
chemokines and that of microglia, resident immune cells in 
the brain. Accumulating evidence indicates that, by targeting 
various genes, particular miRNAs play an important role in 
the development of post-ischaemic inflammatory responses 
(Abdullah et al. 2015; Wang et al. 2018). For instance, trans-
fection of neuronal cells with miR-181c inhibits the expres-
sion of TNF, a prominent pro-inflammatory cytokine during 
the acute phase of an ischaemic injury and thus alleviates 
microglial activation and neuronal cell death. Direct target-
ing of TNF mRNA 3′UTR by miR-181c and subsequent 
decreases in TNF mRNA and protein expression have been 
shown to account for the above-mentioned benefits (Zhang 
et al. 2012). In addition to miR-181c, other miRNAs such as 
miR-216a, miR-3437b and miR-126-3p or -5p are also linked 
with the post-ischaemic cerebral levels of TNF. Hence, it 
was no surprise that attenuation of those particular miR-
NAs protected cerebrovasculature from ischaemic damage 
in animal models of stroke (Pan et al. 2020; Tian et al. 2018; 
Wang et al. 2018). Similar to these findings, the pharmaco-
logical inhibition or genetic deletion of miR-15a/16-1 activ-
ity has also been shown to reduce the expression of TNF 
alongside other pro-inflammatory cytokines, e.g. IL-6 and 
MCP-1 in a murine model of MCAO and improved neurobe-
havioral outcome as ascertained by rotarod, adhesive tape 
removal and foot fault tests at 3 days after MCAO (Yang 
et al. 2017a). In this context, modulation of miR-128 lead-
ing to suppression of p38α MAPK is also associated with 
decreases in pro-inflammatory cytokine release and ensu-
ing inflammatory responses (Mao et al. 2017; Yang et al. 
2017b).
As part of the post-ischaemic inflammatory process, the 
expression of adhesion molecules is upregulated in activated 
endothelial cells which facilitate adherence of leukocytes to 
them and paves the way for BBB disruption. Hence, mitiga-
tion of adhesion molecule expression by miRNAs following 
an ischaemic stroke may be of critical importance to protect 
neurovasculature (Ramiro et al. 2018). In support of this 
notion, administration of miR-126-3p/5p to mice subjected 
to MCAO has led to diminished BBB hyperpermeability, 
neurological impairments, leukocytes infiltration and the 
expression of pro-inflammatory mediators by directly regu-
lating the levels of crucial adhesion molecules, VCAM-1 
and E-selectin (Pan et al. 2020).
Oxidative Stress
Oxidative stress is defined as a condition in which cells are 
subjected to excessive levels of molecular oxygen and its 
chemical derivatives called reactive oxygen species or ROS. 
Reperfusion following cerebral ischaemia evokes excessive 
generation of ROS which in turn induces cellular dysfunc-
tion by peroxidising lipids, denaturing proteins and altering 
intra- and intercellular signalling pathways. At tissue level, 
this dysfunction translates to enhanced platelet aggrega-
tion, vascular contractility, endothelial hyperpermeability 
and reduced cerebral blood flow (Allen and Bayraktutan 
2009). Therefore, modulation of ROS generation during or 
after cerebral ischaemia by miRNA-mediated regulation of 
endogenous pro- and anti-oxidant enzymes may actually 
counterbalance these deleterious effects (Xu et al. 2018).
In accordance with this hypothesis, inhibition of miR-424 
has been shown to protect neurovascular integrity by reduc-
ing the level of ROS and lipid peroxidation and concurrently 
increasing the expression of anti-oxidant MnSOD and extra-
cellular SOD enzyme in mice with MCAO. Although this 
study did not perform luciferase assay to identify the target 
genes for miR-424, attenuation of these protective effects 
through knockdown of Nrf-2 (an important transcription fac-
tor that regulates endogenous anti-oxidant) and inhibition of 
SOD activity confirm the association between this particular 
Cellular and Molecular Neurobiology 
1 3
miRNA and oxidative stress (Liu et al. 2015). In another 
study, administration of miR-93 to mice with MCAO has 
also led to marked increases in the expression of total SOD 
activity and promoted post-stroke recovery through directly 
binding to 3′UTR of Nrf-2 mRNA (Wang et al. 2016).
Cell Death
All pathologies implicated in the pathogenesis of ischaemic 
stroke, namely energy failure, excitotoxicity, inflammation 
and oxidative stress can elicit regulated cell death in penum-
bra, the area surrounding the infarct, within hours to days 
of ischaemic injury and therefore exacerbate neurovascu-
lar damage (Rakkar and Bayraktutan 2016). Apoptosis, the 
classical and well-reported cell death form, can be activated 
through one of the two pathways. In the intrinsic pathway, 
the cell death occurs due to cell stress where the release of 
cytochrome-c from mitochondria plays a crucial role. In the 
extrinsic pathway, the cell death occurs because of signals 
from other cells where interaction between death receptor 
and its ligand on the cell surface plays a critical role.
An increase in the expression of pro-apoptotic genes 
makes up another important cause of cell stress in the intrin-
sic pathway (Chelluboina et al. 2014). This is partly regu-
lated by the modulation of a number of miRNAs, including 
miR-214 and miR-128. Indeed, modulation of miR-214 fol-
lowing cerebral ischaemic injury reduces neuronal apopto-
sis by decreasing pro-apoptotic protein Bax and increasing 
anti-apoptotic protein Bcl-2 expression. While the down-
regulation of Bax may be due to the direct binding of miR-
214 to this protein (Ping et al. 2017), the elevation of Bcl-2 
level may be attributed to the inhibition of calcium overload. 
Namely, suppression of the mRNA-encoding sodium/cal-
cium exchanger 1 (NCX1), a key regulator of calcium influx, 
along with various downstream effectors and pathologies 
that mediate cell death, notably oxidative stress, is thought 
to increase cell survival by upregulation of Bcl-2 expression 
and accounts for the protective role of miR-214 after ischae-
mic injuries (Aurora et al. 2012; Rakkar and Bayraktutan 
2016). miR-128 has also been identified to directly bind to 
3′UTR of Bax and thus increases cell survival (Adlakha and 
Saini 2011). Similarly, direct upregulation of a member of 
Bcl-2 anti-apoptotic protein family, i.e. Bcl-2l11 dramati-
cally decreases neuronal apoptosis and improves post-stroke 
recovery of mice subjected to MCAO by suppressing miR-9 
gene expression (Wei et al. 2016).
As indicated above, in the extrinsic pathway, the inter-
action between the cell surface death receptor (e.g. FasR) 
and its ligand (e.g. FasL) constitutes the main step in the 
initiation of events leading to apoptosis. By decreasing 
the expression of FasR, miRNAs like miR-25 reduce the 
number of apoptotic cells in ischaemic settings. Interest-
ingly, by inhibiting the binding of FasR to its ligand, they 
also establish a balance between the expression of pro- and 
anti-apoptotic proteins and influence the intrinsic pathway 
as a result (Sprick and Walczak 2004; Zhang et al. 2016). 
Intrinsic and extrinsic pathways also interact at the point of 
caspase-3 activation. Caspase-3 is recognised as an execu-
tioner caspase in apoptosis due to its role in coordinating 
the destruction of cellular structures and macromolecules, 
notably cytoskeleton and DNA, respectively (Broughton 
et al. 2009; Shao and Bayraktutan 2014). Through direct 
targeting of caspase-3, a number of miRNAs such as miR-
378 and miR-let-7c-5p have been shown to reduce the rates 
of cellular apoptosis following a cerebral ischaemic injury 
(Fang et al. 2012; Ni et al. 2015).
In addition to apoptosis, miRNA is also involved in the 
induction of other forms of ischaemic injury-mediated 
cell death such as autophagy, necroptosis and ferroptosis. 
Autophagy refers to the degradation of cytoplasmic pro-
teins or organelles in order to produce vital amino acids 
to maintain cell survival in the absence of oxygen and glu-
cose. While a degree of autophagy is thought to be protec-
tive for cellular homeostasis, excessive autophagy causes 
tissue damage and triggers functional aberrances (Zille 
et al. 2019). For instance, inhibition of miR-30a that binds 
to the mRNA of Beclin-1, the key molecule in autophagy, 
has been shown to prevent neuronal death and improve 
behavioural outcome of mice with ischemic stroke (Wang 
et al. 2014a). Necroptosis, on the other hand, is described 
as a type of regulated necrosis that is independent from 
caspase pathway and is characterised by the disruption 
of cell membrane and swelling of organelles (Datta et al. 
2020). It is initiated by an interaction between cell death 
receptor (e.g. TNFR) and its ligand leading to activation 
of receptor-interacting serine/threonine-protein kinase-1 
(RIPK1) and RIPK3. Once activated, RIPKs bind and 
phosphorylate mixed lineage kinase like protein (MLKL) 
whereby create MLKL oligomers which translocate to 
the plasma membrane and induce its permeabilisation 
(Vandenabeele et al. 2010). In this context, inhibition of 
miR-233-5p in an animal model of ischaemic stroke has 
been coupled to reduced neuronal death, infarct volume 
and neurological deficits through its regulatory effect on 
RIPK1/RIPK3/MLKL signalling pathway (Cuomo et al. 
2019; Qin et al. 2016). Ferroptosis is a newly discovered 
form of regulated cell death triggered by the accumulation 
of lethal levels of iron-dependent lipid peroxides and is 
implicated in aggravation of neurovascular damage fol-
lowing a cerebral injury (Ratan 2020). Overexpression of 
miRNAs involved in ferroptosis, notably miR-212-5p, has 
recently been associated with improved learning and spa-
tial memory in an animal model of traumatic brain injury 
by directly regulating prostaglandin-endoperoxide syn-
thase-2 (Ptgs2), a marker of ferroptosis (Xiao et al. 2019).
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BBB Disruption
The unregulated opening of BBB during or after an ischae-
mic stroke causes the accumulation of circulating molecules 
within the brain parenchyma and thus induces formation of 
vasogenic oedema and haemorrhagic transformation, main 
causes of death within the first week of an ischaemic stroke. 
At molecular level, breakdown of BBB is characterised 
by an impairment of tight junctions (TJs) that are formed 
between adjoining brain microvascular endothelial cells 
through the interactions of crucial transmembrane proteins, 
claudin-5, occludin and zonula occludens-1 (ZO-1) (Gibson 
et al. 2014; Winkler et al. 2020). Through close regulation of 
these transmembrane proteins, various miRNAs have been 
shown to actively participate in ischaemic stroke-induced 
BBB leakage. For instance, overexpression of miR-150 
appears to mitigate BBB hyperpermeability, infarct volume 
and neurological impairment in animal models of ischaemic 
stroke by regulating claudin-5 expression and endothelial 
cell survival (Fang et al. 2016). Again, increased expressions 
of occludin and ZO-1 have been shown to account for BBB-
protective effects of miR-130a and miR-155, respectively 
in MCAO rats (Caballero-Garrido et al. 2015; Wang et al. 
2017b).
Aquaporins (AQPs), the plasma membrane water-trans-
porting proteins, also contribute to formation of BBB. 
Indeed, through direct regulation of AQPs, in particular, 
AQP4 which makes up the most abundant AQP in the cen-
tral nervous system, exogenously administered miR-29b and 
miR-145 have been shown to preserve BBB function in mice 
subjected to MCAO (Wang et al. 2015; Zheng et al. 2017).
Predictive Biomarker
Identifying generally healthy individuals who may be 
at risk for stroke is of critical importance to amelio-
rate the devastating impact of this condition globally. A 
large number of modifiable and non-modifiable risk fac-
tors such as hypertension, diabetes, atherosclerosis, age, 
sex and ethnicity are associated with an increased risk 
of stroke (Vijayan and Reddy 2016b). Inevitably, several 
miRNAs connected with the pathogenesis of these risk 
factors, including miR-155 (hypertension), miR-33 (hyper-
lipidaemia), miR-144 and miR-223 (diabetes mellitus) and 
miR-21, miR-126, and miR-320b (atherosclerosis) have 
been proposed as potential predictive markers for stroke 
(Rink and Khanna 2010; Vijayan and Reddy 2020). Given 
that Framingham stroke risk score (FSRS), a widely used 
risk score to predict 10-year probability of cerebrovascu-
lar events in asymptomatic individuals, tends to overes-
timate cerebrovascular events in general population, the 
new markers are desperately needed (Bineau et al. 2009; 
Dufouil et al. 2017; McClure et al. 2014). Exclusion of the 
functional status of endothelium may be the main reason 
for the above-mentioned overestimation of future strokes 
(Flueckiger et al. 2018; Liu and Wang 2016). Endothelial 
dysfunction is strongly associated with the future vascu-
lar diseases in asymptomatic adults. So, adding micro-
vascular endothelial status to the FSRS may improve risk 
discrimination power (Flammer et al. 2012; Prugger et al. 
2013; Zhong et al. 2018). Since several miRNAs have been 
identified as crucial regulators of endothelial function, it 
is possible that they can also, individually or collectively, 
serve as potential predictors of future strokes in general 
population.
In this regard, a large cohort study has reported that 
concurrent analysis of a 3-miRNA combination model, 
composed of miR-1268b, miR-4433b-3p and miR-
6803-5p, exhibit a sensitivity of 80%, specificity of 82% 
and area under receiver curve (AUC) value of 0.89 to pre-
dict future stroke event in asymptomatic adults. As sen-
sitivity and specificity quantify the percentages of true-
positive subjects with disease and true-negative subjects 
without disease, they are regarded as reliable measures 
of predictive biomarkers or diagnostic tests. Since the 
results of sensitivity and specificity might vary accord-
ing to the chosen cut-off point, the area under receiver-
operating characteristic curve was also performed in this 
study to define the optimum cut-off points by plotting the 
sensitivity on the y-axis against specificity on the x-axis. 
Taken together, the observation of remarkably high sen-
sitivity, specificity and AUC value in this study proposes 
the 3-miRNA combination model as an important predic-
tor of future strokes. Although scrutiny of a large sample 
size (1612 participants with no history of stroke and 190 
patients with previous stroke) substantiates the predictive 
value of these miRNAs, homogeneity of study popula-
tion should not be dismissed while interpreting the results 
(Sonoda et al. 2019).
Epidemiological studies assessing the contribution of 
genetic variation to stroke risk report that there is substan-
tial heritability for ischaemic stroke (37.9% for all ischaemic 
stroke), and this varies for different stroke subtypes; 16.1% 
for small-vessel disease, 32.6% for cardioembolic disease 
and 40.3% for large-vessel disease (Bevan et al. 2012). In 
this context, increasing evidence shows that the specific 
single nucleotide polymorphisms (SNPs) in miRNA genes 
may affect the generation and function of mature miRNAs. 
Since SNPs are inherited genetic variations, they can be used 
to predict future cerebrovascular events. In a meta-analysis 
involving 3372 patients with stroke and 4394 controls, SNPs 
in miR-149 have been correlated with a significant increase 
risk of future stroke in East Asian population. This study 
clearly indicates that identification of genetic variation in 
the specific miRNA may be a potential strategy to predict 
risk of future strokes (Du et al. 2017).
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Diagnostic Biomarker
The accurate identification of stroke type is an important 
prerequisite for an immediate start of treatment. Owing to 
its widespread availability and speed, CT scan has become 
the most commonly used imaging procedure for the initial 
diagnosis of stroke type, haemorrhagic or ischaemic. MRI is 
another imaging modality that is occasionally used to diag-
nose strokes. Despite capturing more details compared to 
CT, MRI is a more expensive and relatively less available 
procedure. Besides, to avoid variability in image interpreta-
tion, it is recommended that CT is used as an initial imaging 
procedure (Parody et al. 2015; Wardlaw Joanna et al. 2007).
The panel of protein biomarkers such as activated protein 
C–protein C inhibitor complex (APC–PCI), glial fibrillary 
acidic protein (GFAP) and retinol binding protein 4 (RBP4) 
are potential alternative option to neuroimaging techniques, 
with advantages that can elucidate the underlying mecha-
nism of disease, but they have shown limited diagnostic 
value with regard to blood-based biomarkers in stroke 
patients (Misra et al. 2017). Utilisation of circulating miR-
NAs as a blood-based biomarker in acute stroke patients has 
recently become an attractive and feasible concept (Table 1). 
Unlike intracellular mRNAs, miRNAs exhibit remarkable 
stability and resistance to nuclease digestion as well as other 
harsh conditions such as boiling, low or high pH, extended 
storage and freeze–thaw cycles (Wang et al. 2013). In addi-
tion, analysis of circulatory levels of certain miRNAs can 
help monitor both cerebral and systemic changes after an 
ischaemic stroke (Eyileten et al. 2018). Comprehensive 
evaluation of circulating miRNAs by a gradual approach 
of discovery, validation and replication has pinpointed the 
combination of miR-125a-5p, miR-125b-5p and miR-143-3p 
as an important diagnostic biomarker for ischaemic stroke 
with remarkable sensitivity (85.6%), specificity (76.3%) 
and AUC value (0.90) (Tiedt et al. 2017). In comparison, 
multimodal cranial CT scan has a sensitivity of 72.5% for 
ischaemic stroke while commonly used high-sensitivity bio-
markers like C-reactive protein (0.73 vs 0.90), IL-6 (0.82 vs 
0.90) and neuron-specific enolase (0.69 vs 0.90) have signifi-
cantly lower AUC values than these three miRNAs. Impor-
tantly, despite differentiating ischaemic stroke from transient 
ischaemic attack (TIA), the changes in these miRNA levels 
failed to correlate with infarct volume. Subsequent experi-
ments proving platelets as the major cellular source of these 
miRNAs have explained why changes in these miRNA levels 
do not correlate with infarct volume or neuronal cell death. 
Similar studies have reported that the level of serum miR-
221-3p and miR-382-5p may be an independent predictor of 
acute ischaemic stroke, with AUC values of 0.810 and 0.748, 
respectively (Tsai et al. 2013; Wang et al. 2017a).
In addition to its ability to differentiate patients with 
ischaemic stroke and healthy subjects, miRNAs may also 
be used to distinguish ischaemic stroke from haemorrhagic 
stroke. For instance, in a study involving 97 stroke patients, 
miRNA-124-3p has shown sensitivity of 68.4% and specific-
ity of 71.2%, and miRNA-16 exhibited sensitivity of 94.7% 
and specificity of 35.1% to differentiate ischaemic stroke 
and haemorrhagic stroke. However, as patients within 24 h 
of ischaemic stroke have been recruited for this study, the 
results may not be truly indicative of the acute stroke set-
tings (Leung et al. 2014). Recently, variations observed 
in the level of 25 extracellular miRNAs, e.g. miR-30a-3p, 
miR-224-5p, miR-98-3p, miR-629-5p and miR-320a, after 
stroke have also been shown to reliably differentiate ischae-
mic strokes from haemorrhagic ones with an AUC value of 
0.813. However, large cohort studies focusing on a small 
number of these extracellular miRNAs may better validate 
particular miRNAs as diagnostic markers for stroke (Kalani 
et al. 2020).
A recent integrated meta-analysis, bioinformatics and 
data mining study investigating biomarkers for ischaemic 
strokes specifically induced by inflammation or infection 
has demonstrated miR-320b and miR-320d as key miRNAs 
involved in this process. Indeed, these miRNAs have been 
implicated in the pathogenesis of ischaemic strokes evoked 
by atypical infections caused by helicobacter pylori, amoe-
bae and legionella bacteria or inflammation caused by sys-
temic lupus erythematosus and asthma. Taken together, data 
discussed so far indicate that different miRNAs may serve 
as diagnostic marker for ischaemic stroke stemming from 
different causes (Xie et al. 2020).
Prognostic Biomarker
A good prognostic biomarker for stroke should be able to 
predict short- and long-term disease-related complications, 
identify patients who may benefit most from the acute inter-
ventions and monitor the efficacy of the applied treatment 
over a specified time interval. Due to the considerable stabil-
ity of miRNAs in the circulation and their extensive regula-
tory roles in cellular and molecular events after a cerebral 
injury, numerous studies have proposed miRNAs as crucial 
potential prognostic biomarkers for patients with ischaemic 
stroke (Martinez and Peplow 2016). For instance, the circu-
lating level of miR-128, associated with neuroinflammation 
and neuronal cell death, is positively correlated with infarct 
volume, NIH stroke scale (NIHSS) score at 7 days and modi-
fied Rankin Scale (mRS) score at 3 months after an ischae-
mic stroke (Liu et al. 2019). Similarly, the combination of 
miR-124-3p, miR-125b-5p and miR-192-5p is correlated 
with the extent of neurological deterioration in ischaemic 
stroke patients treated with rtPA or underwent mechanical 
thrombectomy, with an AUC value of 0.803, a sensitivity of 
88% and a specificity of 65.22%. Considering the inclusion 
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of a small sample size in this study, these findings need to 
be confirmed by other studies (He et al. 2019a).
Haemorrhagic transformation (HT), referring to a wide 
spectrum of ischaemia-related cerebral haemorrhage, is a 
frequent complication of ischaemic stroke, particularly in 
patients who have been given thrombolytic therapy. It consti-
tutes one of the main reasons leading to elevations in mortal-
ity and morbidity following ischemic strokes. Several miR-
NAs that are inextricably intertwined with the expression 
of basement membrane-degrading enzyme MMP-9, notably 
miR-21-5p (AUC value of 0.677), miR-206 (AUC value of 
0.687) and miR-3123 (AUC value of 0.661) appear to predict 
the risk of HT in patients with cardioembolic stroke (Abdul-
lah and Bayraktutan 2016; Zheng et al. 2019).
It is known that individuals who suffer a first stroke are at 
considerably greater risk of having another stroke compared 
to general population. It is also well known that stroke sur-
vivors who suffer a second stroke are ~ 3 times more likely 
to die from than  those who do not experience a second 
stroke (Jørgensen et al. 1997). Scrutiny of the correlation 
between the level of atherosclerosis-related miRNAs and 
the risk of stroke recurrence has identified miR-17 as an 
important miRNA during the first 24 months after a stroke. 
However, only 120 participants (83 acute ischemic stroke 
patients and 37 controls) from Korea were studied in this 
study. Hence, further studies with bigger sample size and 
heterogenic participants are required to establish the role of 
this particular miRNA in ischaemic stroke (Kim et al. 2015)
Therapeutic Strategy
Given that the alterations in expression of specific miRNAs 
contribute to the pathophysiological mechanisms underly-
ing ischaemic stroke, manipulation of their levels through 
miRNA agomir or antagomirs may be a potential therapeu-
tic approach (Table 2). For example, restoration of circulat-
ing levels of miR-424 by its agomir helped reduce cerebral 
infarct and oedema volumes in a mouse model of transient 
ischaemic stroke by inhibiting neuronal cell death, micro-
glia activation and oxidative injury (Liu et al. 2015; Zhao 
et al. 2013). Likewise, pre-treatment with miR-200c antago-
mir significantly reduced infarct volume and neurological 
impairment in mice subjected to MCAO by directly regu-
lating the protein expression of Reelin, an essential extra-
cellular matrix protein for neuronal survival. In this study, 
the neurological deficits were measured by a neurological 
grading scale in which scores of 0 and 4 were defined by no 
observable neurological deficit and inability to walk, respec-
tively. Inhibition of miR-200c dramatically accelerated the 
speed of recovery from ischaemic stroke (Stary et al. 2015).
Following cerebral ischaemia, neural progenitor cells 
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Table 2  Animal studies investigating the therapeutic efficacy of miRNA in the setting of ischaemic stroke
Agent (Author) Design Key findings
miR-27b antagomir Model: MCAO mice Increased neuronal survival and promoted neurogenesis by 
directly regulating AMPK expression
(Wang et al. 2019) Delivery strategy: NA Improved functional outcome and spatial memory
Route: intravenous
Time of administration: day 7, 14 and 28 after MCAO
miR-107 antagomir Model: MCAO rats Suppressed VEGF mRNA and protein expression and pro-
moted angiogenesis through directly binding to Dicer-1
(Li et al.) Delivery strategy: NA Reduced infarct volume and improved capillaries in ischae-
mic boundary zone
Route: intraventricular
Time of administration: 1 h after MCAO
miR-126 agomir Model: MCAO mice Promoted vascular remodelling and neurogenesis
(Qu et al.) Delivery strategy: lentiviral vector Improved neurobehavioral recovery and reduced brain 
atrophy volume
Route: intracerebral
Time of administration: 7 days after MCAO
miR-126-Primed EPCs Model: MCAO mice Increased proliferation, migration and tubulogenic capacity 
of EPCs
(Pan et al.) Delivery strategy: lentiviral vector Decreased ROS and increased NO production of EPCs by 
activating PI3K/Akt/eNOS pathway
Route: intravenous miR-126 augmented the therapeutic efficacy of EPCs and 
helped attenuate infarct volume and neurological deficits 
while improving cerebral blood flow, microvascular 
density and angiogenesis
Time of administration: 2 h after MCAO
miR-126-3p or -5p agomir Model: MCAO mouse Reduced cerebral infarct and oedema volumes
(Pan et al.) Delivery strategy: lentiviral vector Improved zonula occludens-1 and occlusion expressions 
and maintained BBB function
Route: stereotactic injection Reduced pro-inflammatory cytokine (IL-1β and TNF) and 
adhesion molecule (VCAM-1 and E-selectin) expressions
Time of administration: 2 weeks before MCAO
miR-132 agomir Model: MCAO mice Suppressed MMP-9 expression and maintained tight junc-
tion VE-cadherin and β-catenin levels
(Zuo et al. 2019) Route: intraventricular Reduced infarct and oedema volumes, as well as neurologi-
cal deficits
Delivery strategy: NA
Time of administration: 2 h before MCAO
miR-155 antagomir Model: distal MCAO mouse Improved blood flow and microvascular integrity and 
reduced neuronal damages in the peri-infarct area
(Caballero-Garrido et al.) Delivery strategy: novel locked nucleic acid technology Reduced infarct size and neurological impairments
Route: intravenous Maintained the integrity of tight junctions through 
improved zonula occluden 1 protein
Time of administration: 48 h after MCAO Prevented post-ischaemic inflammation by decreasing 
cytokine and chemokine gene expressions
miR-195 agomir Model: MCAO rats Decreased inflammatory response and neuronal cell death 
via direct suppression of NF-κB and Sema3A/Cdc42/
JNK signalling pathways
(Cheng et al.) Delivery strategy: lentiviral vector Stimulated proliferation and mobilisation of neural stem 
cells toward infarct area
Route: intravenous Improved neurological function and reduced infarct size
Time of administration: 6 h after MCAO
miR-195 agomir Model: MCAO rats Reduced neuronal cell death by downregulating KLF-5 and 
JNK expressions
(Chang et al. 2020) Delivery strategy: rAAV2/EGFP vector Decreased infarct volume and neurological deficits
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Table 2  (continued)
Agent (Author) Design Key findings
Route: Intravenous Promoted neuronal growth, axonal regeneration and synap-
tic remodelling
Time of administration: Not available
miR-200c antagomir Model: MCAO mice Increased neuronal survival rates through directly binding 
to Reelin
(Stary et al.) Delivery strategy: NA Reduced infarct volume and neurological deficits
Route: intraventricular
Time of administration: 24 h before MCAO
miR-214 agomir Model: MCAO mice Inhibited neuronal cell death by directly binding to Bax 
protein
(Ping et al.) Delivery strategy: NA Improved neurological outcomes and reduced infarct 
volume
Route: intraventricular
Time of administration: 48 h before MCAO
miR-216a agomir Model: MCAO mice Downregulated pro-inflammatory mediators, e.g. iNOS, 
MMP-9, TNF and IL-1β by directly targeting JAK2/
STAT signalling pathway
(Tian et al.) Delivery strategy: NA Improved functional outcomes and reduced infarct volume
Route: intraventricular
Time of administration: 10 min after MCAO
miR-365 antagomir Model: MCAO rats miR-365 targets Pax6, a transcription factor account for 
conversion of astrocytes to neurons
(Mo et al. 2018) Delivery strategy: NA Promoted neurogenesis by inducing new mature neuron 
generation derived from astrocytes in the ischemic 
striatum
Route: intraventricular Reduced neurological deficits and infarct outcome
Time of administration: 30 min after MCAO
miR-384-5p agomir Model: MCAO mouse Promoted proliferation and angiogenesis of EPCs by regu-
lating Notch signalling pathway
(Fan et al. 2020) Delivery strategy: NA Decreased infarct size and neuronal cell death
Route: Intraventricular
Time of administration: 2 days before MCAO
miR-1906 agomir Model: MCAO mice Reduced post-stroke inflammatory response by directly 
targeting TLR-4
(Xu et al. 2017) Delivery strategy: NA Decreased neurological deficits and infarct volume
Route: intraventricular
Time of administration: not provided
miR-3473b antagomir Model: MCAO mouse Prevented neuroinflammation by downregulating mRNA 
and protein expression of pro-inflammatory mediators 
like iNOS, COX-2, TNF and IL-6
(Wang et al. 2019) Delivery strategy: NA Reduced infarct volume and improved neurobehavioural 
recovery
Route: intraventricular
Time of administration: 3 days prior to MCAO
AMPK 5′ adenosine monophosphate-activated protein kinase, Cdc42 cell division control protein 42, COX-2 cyclooxygenase-2, eNOS endothe-
lial nitric oxide synthase, EPCs endothelial progenitor cells, IL-1β interleukin-1β, IL-6 interleuikin-6, iNOS inducible nitric oxide synthase, JAK 
janus kinase, JNK c-Jun N-terminal kinase, KLF-5 kruppel-like factor, MCAO middle cerebral artery occlusion, miRNA microRNA, MMP-9 
matrix metallopeptidase-9, mRNA messenger ribonucleic acid, NA not applicable, NF-κB nuclear factor-κB, NO nitric oxide, Pax6 paired box 
protein-6, PI3K phosphoinositide 3-kinases, rAAV2/EGFP recombinant adeno-associated virus vector/E-green fluorescent protein, ROS reactive 
oxygen species, Sema3A semaphorin 3A, STAT signal transducer and activator of transcription, TLR-4 toll-like receptor-4, TNF tumour necrosis 
factor, VCAM-1 vascular cell adhesion protein-1, VEGF vascular endothelial growth factor
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and differentiate into few other cell lines, including neurons, 
glia and oligodendrocytes, to promote post-stroke neurogen-
esis (Hoehn Benjamin et al. 2005). In this regard, inhibition 
of miR-17-92 cluster has been found to induce prolifera-
tion, differentiation and survival of NPCs in subventricu-
lar zone (SVZ) through direct targeting of phosphatase and 
tensin homologue. In accordance with this finding, treat-
ments with miR-17-92 cluster antagomir have improved 
functional outcome and neuronal plasticity in the cerebral 
ischemic boundary zone of rats subjected to MCAO (Liu 
et al. 2013; Xin et al. 2017). Similar to NPCs, endothelial 
progenitor cells (EPCs), released from the bone marrow, also 
detect and repair endothelial damage through differentiat-
ing into mature endothelial cells or mediating the release of 
various growth factors in response to an ischaemic injury 
(Abdulkadir et al. 2020; Bayraktutan 2019). The number 
as well as proliferative, migratory and tube-forming capac-
ity of circulating EPCs after cerebral damage are regulated 
by overexpression of miR-126. When used together with 
miR-126, EPCs were significantly more effective in reducing 
infarct volume and neurological deficits in a mouse model 
of ischaemic stroke (Pan et al. 2018). Along with generating 
endogenous stem cells to promote angiogenesis and neu-
rogenesis, the treatment strategy after an ischaemic stroke 
should also aim to maintain the viability of resident cerebral 
endothelial cells. In this context, intraventricular adminis-
tration of miR-107 agomir to a rodent model of permanent 
ischaemic stroke has led to increases in mRNA and protein 
expression of VEGF and, as a result, promoted migratory 
and tubulogenic capacity of resident cerebral endothelial 
cells and reduced overall infarct volume by improving num-
ber of capillaries in the ischaemic boundary zone (Zhu et al. 
2015).
Intriguingly, no clinical trial has so far investigated the 
protective effect of miRNA-based approaches in stroke 
patients. A phase 2 multicentre randomised-clinical trial 
exploring the safety and feasibility of miRNA-based 
approaches has shown that administration of Miravirsen, a 
miR-122 antagomir to patients with chronic hepatitis C virus 
(HCV) genotype 1 infection effectively reduces HCV RNA 
levels without showing any dose-dependent toxicity (Jans-
sen et al. 2013).
Future Perspectives
Accumulating evidence indicates that changes in quantity of 
circulating miRNAs may serve as predictive, diagnostic or 
prognostic biomarkers for ischaemic stroke. Evidence also 
indicates that manipulation of certain miRNAs may be an 
efficacious therapeutic strategy to mitigate the burden of 
ischaemic stroke. Nevertheless, several issues need to be 
addressed before translating hitherto experimental findings 
into clinical settings. Due to variations in the source of 
miRNAs and in protocols used to detect, extract and isolate 
them, markedly different levels of miRNA and contradic-
tory outcomes have been reported in different studies. For 
example, while circulating level of miR-223 was shown to 
negatively correlate with NIHSS score and infarct volume in 
an observational study involving 79 acute ischaemic stroke 
patients and 75 healthy subjects, in another study, the level 
of exosomal miR-223 was shown to positively correlate with 
NIHSS and mRS scores but not infarct volume (Chen et al. 
2017; Wang et al. 2014b).
In addition, common protocols to detect circulating miR-
NAs, i.e. RT-PCR and microarray may have serious limi-
tations to consistently detect changes in different miRNA 
expressions thereby necessitating exploration of alterna-
tive more reliable, faster and cheaper approaches (Ferraro 
et al. 2016; Vaca 2014). Isothermal PCR and ODG platform 
(optoi-destiNA genomics), an innovative platform that was 
established by the integration of a unique chemical-based 
method for nucleic acid detection with a novel silicon pho-
tomultiplier-based reader, has recently emerged as impor-
tant diagnostic utilities for direct qualitative and quantitative 
measurement of miRNAs in biological samples (Detassis 
et al. 2019; Gines et al. 2020).
Moreover, the discrete patterns of miRNAs expression at 
different time points of cerebral ischaemic injury potentially 
transform the therapeutic approach from a single-point, sin-
gle-drug stroke therapy to a multiple-time-point and multi-
drug therapeutic approach (Cai et al. 2019). For instance, 
miR-126 exhibits a crucial role for angiogenesis and neu-
rogenesis and its level is markedly decreased at day 7 fol-
lowing an ischaemic injury. Hence, administration of miR-
126 agomir at this time point is correlated with improved in 
vascular remodelling, neurogenesis and neurobehavioural 
outcome of MCAO mice (Qu et al. 2019). miR-195, on the 
other hand, plays an important role in regulating inflamma-
tory responses after an ischaemic attack and its level begins 
to decrease from 3 h to 3 days in patients with ischaemic 
stroke. Hence, it is no surprise that the administration of 
miR-195 agomir within 6 h after cerebral ischaemic injury 
has been found to reduce the inflammatory response, neuro-
logical deficits and infarct size in MCAO rats (Cheng et al. 
2019; Guang et al. 2018).
Since most studies reporting on the potential predic-
tive, diagnostic and prognostic role of miRNA recruited 
homogenous populations and analysed limited number of 
samples, further studies with heterogonous participants are 
required to ascertain the true value of miRNAs as biomark-
ers. Although therapeutic efficacy of miRNA agomirs or 
antagomirs has been established in experimental settings, 
the optimum route and time point for their delivery remain 
to be established. Given that the short therapeutic window 
for thrombolysis renders most patients ineligible to receive 
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rtPA, it is crucial to study and validate effectiveness of dif-
ferent miRNAs beyond the acute phase of stroke (Hisham 
and Bayraktutan 2013). Several studies attempting to address 
this critical issue exist and are listed in Table 2.
As a route of medication administration, intravenous 
route represents one of the most preferred approaches in 
clinical practice due to its safety and its ease of use. None-
theless, due to structural and functional properties of the 
BBB, most exogenous substances administered through this 
route cannot enter the central nervous system. Although, 
direct administration of medication into the brain (i.e. intra-
ventricular) may overcome such hurdles, such invasive pro-
cedures are difficult and associated with significant adverse 
effects. Intranasal administration may also be an effective 
delivery strategy in that agents inhaled appear to cross the 
BBB with ease and improved functional outcomes in some 
animal models of disease like Alzheimer (Mai et al. 2019). 
Novel delivery strategies utilising viral vectors, e.g. adeno-
associated virus, or non-viral vectors, e.g. liposomes and 
exosomes, may mitigate most risks associated with other 
routes. Furthermore, the miRNAs inserted into a viral or 
non-viral vector can be continually expressed, resulting in 
strong downregulation or upregulation of miRNA of interest 
in any disease setting including ischaemic stroke (Li et al. 
2018).
It is noteworthy here that an alternative approach to vali-
date miRNA targets should be explored to better understand 
how individual miRNAs regulate their target gene expres-
sion. It is thought that most miRNA–mRNA interactions 
involve the seed region at the 5′ end of the miRNA. How-
ever, most seed sequences only have seven or eight nucleo-
tides; thus, one mRNA may have multiple miRNA targets 
or one miRNA can bind to multiple mRNAs. Therefore, 
binding of miRNAs to unintended mRNA(s) may poten-
tially cause adverse effects due to up- or down-regulation of 
nonspecific genes (Li et al. 2013).
Future clinical studies should also consider the fact that 
most of the currently available studies investigating the 
effects of miRNA have been performed using animal models 
of ischaemic stroke and the affinity of miRNA to its target 
gene may be different in humans (Sundermeier and Palcze-
wski 2016).
Conclusion
Discovery of an intricate involvement of various miRNAs in 
the pathogenesis of major events, such as excitotoxicity, oxi-
dative stress and BBB damage, promoting ischaemic stroke 
has implied that some of these miRNAs may serve as impor-
tant therapeutics or clinical biomarkers for stroke. Despite 
availability of evidence demonstrating that different miR-
NAs can serve as blood-based biomarkers for the prediction, 
diagnosis and prognosis of ischaemic stroke, further studies 
with larger sample size are required to ascertain their value 
and reliability in heterogenous populations. Again, available 
data indicate that treatments with various miRNA agomirs 
or antagomirs remarkably improve neurological outcome 
while preventing infarct and oedema expansion in animal 
models of ischaemic stroke through in part promoting the 
recruitment and differentiation of progenitor cells. Although 
evidence regarding the time of treatment, administrative 
routes and delivery strategy continue to accumulate, further 
evidence is needed to devise a standard protocol for the use 
of miRNA as therapeutics in clinical settings.
In conclusion, miRNAs possess great potential to serve 
as early predictive markers, point-of-care diagnostic tools, 
reliable prognostic markers and efficacious therapeutics for 
ischaemic stroke.
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